NovaBridge Biosciences and its subsidiary Visara announced positive topline results from the Phase 2a study of VIS-101 in wet AMD, showing mean BCVA improvements of >10 ETDRS letters, median CST reductions of 100-150 µm, and potential best-in-class durability with ~two thirds of patients retreatment-free at 4 months. A Phase 2b study is expected in H2 2026 and global Phase 3 in 2027.
Key takeaways
VIS-101 Phase 2a study enrolled 38 wet AMD patients in China, randomized 2:1 to 6mg (n=25) and 3mg (n=13) doses
Mean BCVA improvement >10 ETDRS letters in both 3mg and 6mg cohorts
Median CST reduction of 100-150 µm observed
~Two thirds of patients retreatment-free at 4 months, ~half at 6 months
Favorable safety profile with no dose-limiting toxicity; treatment-related TEAEs 0% in 3mg, 8% in 6mg
Phase 2b dose-determining study to begin H2 2026; global Phase 3 in 2027